Cargando…

WT1-specific TCRs directed against newly identified peptides install antitumor reactivity against acute myeloid leukemia and ovarian carcinoma

BACKGROUND: Transcription factor Wilms’ tumor gene 1 (WT1) is an ideal tumor target based on its expression in a wide range of tumors, low-level expression in normal tissues and promoting role in cancer progression. In clinical trials, WT1 is targeted using peptide-based or dendritic cell-based vacc...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Amerongen, Rosa A, Hagedoorn, Renate S, Remst, Dennis F G, Assendelft, Danique C, van der Steen, Dirk M, Wouters, Anne K, van de Meent, Marian, Kester, Michel G D, de Ru, Arnoud H, Griffioen, Marieke, van Veelen, Peter A, Falkenburg, J H Frederik, Heemskerk, Mirjam H M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214430/ https://www.ncbi.nlm.nih.gov/pubmed/35728869 http://dx.doi.org/10.1136/jitc-2021-004409

Ejemplares similares

T cell receptor engineering of primary NK cells to therapeutically target tumors and tumor immune evasion
por: Morton, Laura T, et al.
Publicado: (2022)

Direct identification of neoantigen-specific TCRs from tumor specimens by high-throughput single-cell sequencing
por: Lu, Yong-Chen, et al.
Publicado: (2021)

First immunotherapeutic CAR-T cells against the immune checkpoint protein HLA-G
por: Anna, François, et al.
Publicado: (2021)

Valproic acid increases CAR T cell cytotoxicity against acute myeloid leukemia
por: Wen, Jingjing, et al.
Publicado: (2023)

PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer
por: van Amerongen, Rosa A., et al.
Publicado: (2023)

Low-dose interferon-alpha preconditioning and adoptive cell therapy in patients with metastatic melanoma refractory to standard (immune) therapies: a phase I/II study
por: Verdegaal, Els, et al.
Publicado: (2020)

PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells
por: Bajor, Malgorzata, et al.
Publicado: (2022)

Patient-reported outcomes in CD30-directed CAR-T cells against relapsed/refractory CD30+ lymphomas
por: Tschernia, Nicholas P, et al.
Publicado: (2023)

Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy
por: Liu, Xin, et al.
Publicado: (2022)

Metabolic reprogramming via an engineered PGC-1α improves human chimeric antigen receptor T-cell therapy against solid tumors
por: Lontos, Konstantinos, et al.
Publicado: (2023)

IL15 modification enables CAR T cells to act as a dual targeting agent against tumor cells and myeloid-derived suppressor cells in GBM
por: Zannikou, Markella, et al.
Publicado: (2023)

Targeting sphingosine 1-phosphate receptor 3 inhibits T-cell exhaustion and regulates recruitment of proinflammatory macrophages to improve antitumor efficacy of CAR-T cells against solid tumor
por: Gao, Ge, et al.
Publicado: (2023)

Timed adoptive T cell transfer during chemotherapy in patients with recurrent platinum-sensitive epithelial ovarian cancer
por: Verdegaal, Els M E, et al.
Publicado: (2023)

Neoantigen vaccine-induced CD4 T cells confer protective immunity in a mouse model of multiple myeloma through activation of CD8 T cells against non-vaccine, tumor-associated antigens
por: Bekri, Selma, et al.
Publicado: (2022)

Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma
por: Makkouk, Amani, et al.
Publicado: (2021)

Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2(+) pediatric solid tumors and in vivo survival of xenografted immunodeficient NSG mice
por: Chu, Yaya, et al.
Publicado: (2021)

CBLB ablation with CRISPR/Cas9 enhances cytotoxicity of human placental stem cell-derived NK cells for cancer immunotherapy
por: Guo, Xuan, et al.
Publicado: (2021)

Serpin B9 controls tumor cell killing by CAR T cells
por: Kimman, Thomas, et al.
Publicado: (2023)

Influence of DM-sensitivity on immunogenicity of MHC class II restricted antigens
por: Bernhardt, Anna Luise, et al.
Publicado: (2021)

41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo
por: Baroni, Matteo Libero, et al.
Publicado: (2020)

AKT inhibition generates potent polyfunctional clinical grade AUTO1 CAR T-cells, enhancing function and survival
por: Mehra, Vedika, et al.
Publicado: (2023)

Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release
por: Park, Jeong A, et al.
Publicado: (2021)

Adaptive single-KIR(+)NKG2C(+) NK cells expanded from select superdonors show potent missing-self reactivity and efficiently control HLA-mismatched acute myeloid leukemia
por: Haroun-Izquierdo, Alvaro, et al.
Publicado: (2022)

Indomethacin-induced oxidative stress enhances death receptor 5 signaling and sensitizes tumor cells to adoptive T-cell therapy
por: Aboelella, Nada S, et al.
Publicado: (2022)

PD-L1 blockade restores CAR T cell activity through IFN-γ-regulation of CD163+ M2 macrophages
por: Yamaguchi, Yukiko, et al.
Publicado: (2022)

Forecasting immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor t-cell therapy
por: Amidi, Yalda, et al.
Publicado: (2022)

GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma
por: Gargett, Tessa, et al.
Publicado: (2022)

Production and characterization of virus-free, CRISPR-CAR T cells capable of inducing solid tumor regression
por: Mueller, Katherine P, et al.
Publicado: (2022)

Skin dendritic cells in melanoma are key for successful checkpoint blockade therapy
por: Prokopi, Anastasia, et al.
Publicado: (2021)

Costimulation of γδTCR and TLR7/8 promotes Vδ2 T-cell antitumor activity by modulating mTOR pathway and APC function
por: Wang, Huaishan, et al.
Publicado: (2021)

Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors
por: Foster, Jessica B, et al.
Publicado: (2022)

Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering
por: Michels, Kathryn R, et al.
Publicado: (2023)

IL-15 mediated expansion of rare durable memory T cells following adoptive cellular therapy
por: Kohli, Karan, et al.
Publicado: (2021)

TCR-engaging scaffolds selectively expand antigen-specific T-cells with a favorable phenotype for adoptive cell therapy
por: Tvingsholm, Siri Amanda, et al.
Publicado: (2023)

Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses
por: Brempelis, Katherine J, et al.
Publicado: (2020)

Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia
por: Levine, John E, et al.
Publicado: (2021)

Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3
por: Shah, Bijal D, et al.
Publicado: (2023)

Bone marrow MSC from pediatric patients with B-ALL highly immunosuppress T-cell responses but do not compromise CD19-CAR T-cell activity
por: Zanetti, Samanta Romina, et al.
Publicado: (2020)

Point mutation in CD19 facilitates immune escape of B cell lymphoma from CAR-T cell therapy
por: Zhang, Zhen, et al.
Publicado: (2020)

Adherent cell depletion promotes the expansion of renal cell carcinoma infiltrating T cells with optimal characteristics for adoptive transfer
por: Braun, Mitchell W, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9b9b715b19q36n1ri3a001o5ms